| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention relates to novel derivatives of cycloalkylamines, possessing inhibiting activity with respect to, at least, one monoamine transporter, selected from group, consisting of serotonin transporter, dopamine transporter and norepinephrine transporter. In formula (IV): n equals 1; s equals 1; Y and Z each independently represents halogen; X represents OR 5 ; where R 5 stands for H or non-substituted C 1 -C 10 alkyl; A represents H, non-substituted C 1 -C 10 alkyl or halogen; R 1 and R 2 each independently represents H; R 3 and R 4 each independently represents H or on-substituted C 1 -C 10 alkyl. n EFFECT: invention relates to pharmaceutical composition, containing said compounds and to method of treatment or prevention of neurological disorder or eating disorder, mediated by activity of monoamine transporter, selected from group, consisting of serotonin transporter, dopamine transporter and norepinephrine transporter, such as depression, neurodegenerative disease, abuse with psychoactive substances, fibromyalgia, pain, sleep disorder, syndrome of attention-deficit disorder, syndrome of attention-deficit disorder with hyperactivity, restless legs syndrome, schizophrenia, anxiety, obsessive-compulsive disorder, panic disorder, post-traumatic stress, premenstrual dysphoria. n 35 cl, 6 dwg, 8 ex |